SCHEMBL781569

SCHEMBL781569

O=C(CBr)O[N+]1(O)C(=O)CCC1=O

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3517149 0.84
SCHEMBL1177488 0.81
SCHEMBL1078274 0.81
SCHEMBL19549311 0.81 TSHR (0.34)
SCHEMBL10972293 0.78
SCHEMBL9442582 0.78
Hydrogen Sulfide SCHEMBL8530806 0.76
SCHEMBL1505284 0.75 TSHR (0.42)
SCHEMBL181106 0.75 ALDH1A1 (0.34) ALDH1A1
SCHEMBL15110455 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111565707-A Devices and methods for delivering therapeutics 森玛治疗公司 2020-08-21 CN claimed
JP-2009508852-A 2009-03-05 JP claimed
EP-1973952-A1 CONJUGATE COMPRISING PHARMACEUTICAL ACTIVE COMPOUND COVALENTLY BOUND TO MUCOADHESIVE POLYMER AND TRANSMUCOSAL DELIVERY METHOD OF PHARMACEUTICAL ACTIVE COMPOUND USING THE SAME Gwangju Institute of Science and Technology (KR) 2008-10-01 EP claimed
WO-2007083984-A1 CONJUGATE COMPRISING PHARMACEUTICAL ACTIVE COMPOUND COVALENTLY BOUND TO MUCOADHESIVE POLYMER AND TRANSMUCOSAL DELIVERY METHOD OF PHARMACEUTICAL ACTIVE COMPOUND USING THE SAME GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2007-07-26 WO claimed
JP-3184999-A None JP disclosed
US-20240192236-A1 Compounds and Methods for Use in Detecting Gabapentin ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT 2024-06-13 US disclosed
US-11905323-B2 Recombinant chimeric protein for selectins targeting Bracco Suisse (CH) 2024-02-20 US disclosed
US-11867705-B2 Compounds and methods for use in detecting gabapentin ARK DIAGNOSTICS, INC. (US) 2024-01-09 US disclosed
EP-4213943-A1 COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE The University Of Montana (US) 2023-07-26 EP disclosed
US-11525835-B2 Compounds and methods for use in detecting gabapentin ARK DIAGNOSTICS, INC. (US) 2022-12-13 US disclosed
US-20220389080-A1 RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING BRACCO SUISSE SA (CH) 2022-12-08 US disclosed
US-11370826-B2 Recombinant chimeric protein for selectins targeting BRACCO SUISSE SA (CH) 2022-06-28 US disclosed
WO-1998028626-A9 OPTIMIZATION OF GENE DELIVERY AND GENE DELIVERY SYSTEMS 1998-10-29 WO disclosed
EP-0786087-A1 POLYPEPTIDE-DENDRIMER COMPLEXES DADE INTERNATIONAL INC. (US) 1997-07-30 EP disclosed
US-5635157-A RADIOIMMUNOASSAY BROOKHAVEN SCIENCE ASSOCIATES 1997-06-03 US disclosed
US-5607659-A Directed biodistribution of radiolabelled biotin using carbohydrate polymers NEORX CORPORATION (US) 1997-03-04 US disclosed
WO-1997007398-A1 POLYPEPTIDE-DENDRIMER COMPLEXES DADE INTERNATIONAL INC. (US) 1997-02-27 WO disclosed
US-5292938-A Medical diagnosis; higher and more prolonged tumor uptake, lower retention in kidneys, bones and livers ASSOCIATED UNIVERSITIES, INC. (US) 1994-03-08 US disclosed
US-5095097-A Diagnostics BEHRINGWERKE AKTIENGESELLSCHAFT (DE) 1992-03-10 US disclosed
JP-H03184999-A MAGNETIC PROTEIN CONJUGATE, PREPARATION OF THE SAME BEHRINGWERKE AG 1991-08-12 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240192236-A1 Compounds and Methods for Use in Detecting Gabapentin GABRE, GABRG3, GABRB2 TRPA1 2091/4885ALDH1A1 1863/4885
US-11525835-B2 Compounds and methods for use in detecting gabapentin GABRE, GABRG3, GABRB2 TRPA1 2091/4885ALDH1A1 1863/4885
US-11905323-B2 Recombinant chimeric protein for selectins targeting SELPLG, SELL, SELE TRPA1 3393/4885ALDH1A1 2114/4885
US-20220389080-A1 RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING SELPLG, SELL, SELE TRPA1 3393/4885ALDH1A1 2114/4885
US-11867705-B2 Compounds and methods for use in detecting gabapentin GABRE, GABRG3, GABRB2 TRPA1 2091/4885ALDH1A1 1863/4885
US-11370826-B2 Recombinant chimeric protein for selectins targeting SELPLG, SELL, SELE TRPA1 3393/4885ALDH1A1 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.